0
Original Research: COPD |

Treatment With AM3 Restores Defective T-Cell Function in COPD Patients*

Eduardo Reyes, PhD; Alfredo Prieto, PhD; Antonio de la Hera, MD, PhD; Pilar de Lucas, MD, PhD; Rudolfo Alvarez-Sala, MD, PhD; José Luis Alvarez-Sala, MD, PhD; Melchor Alvarez-Mon, MD, PhD
Author and Funding Information

*From the Laboratory of Immune System Diseases and Oncology (Drs. Reyes, Prieto, and de la Hera), CNB-CSIC Research and Development Associated Unit, Department of Medicine, University of Alcalá; Pulmonary Service (Dr. Lucas), Hospital Universitario Gregorio Marañón; Pulmonary Service (Dr. R. Alvarez-Sala), Hospital Universitario La Paz; Pulmonary Service (Dr. J Alvarez-Sala), Hospital Universitario San Carlos; and Immune System Diseases and Oncology Service (Dr. Alvarez-Mon), Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Madrid, Spain.

Correspondence to: Melchor Alvarez-Mon, MD, PhD, Departamento de Medicina, Universidad de Alcalá, Carretera Madrid-Barcelona, Km 33,600, E-28871 Alcalá de Henares, Madrid, Spain; e-mail: eduardo.reyes@uah.es



Chest. 2006;129(3):527-535. doi:10.1378/chest.129.3.527
Text Size: A A A
Published online

Background: Lymphocyte alterations have been associated with an increased prevalence of acute respiratory infections in COPD patients. AM3 is an oral immunomodulator that normalizes the defective functions of peripheral blood natural killer and phagocytic cells in COPD patients and improves their health-related quality of life.

Objectives: To characterize putative systemic abnormalities of the T-cell compartment in COPD patients, and to investigate whether AM3 can restore such abnormalities.

Design: The study was a randomized, prospective, double-blind, placebo-controlled trial in a cohort of COPD patients. The results were also compared to those of nonsmoker and ex-smoker healthy control subjects.

Setting: Outpatient departments of four hospitals.

Patients: Seventy COPD patients were randomized to receive either AM3 or a placebo orally for 90 consecutive days. Populations of 36 healthy nonsmokers and 36 healthy ex-smokers were used as control subjects.

Measurements: Peripheral blood mononuclear cell (PBMC) proliferation and production of interleukin (IL)-2, IL-4, IL-12p40, tumor necrosis factor-α, and interferon (IFN)-γ proteins in response to the T-cell polyclonal mitogens were assessed at baseline and at the end of treatment.

Results: The proliferative response was significantly decreased in COPD patients. Decreased production of IFN-γ was the only defect in the profiles of the cytokine measures, and was selectively observed in COPD patients, but not in nonsmoker and ex-smoker healthy control subjects. Treatment with AM3 significantly restored the PBMC proliferative response to polyclonal mitogens and significantly promoted stimulated IFN-γ production in these patients. The normalization of these proliferative responses was not related to significant variations in the numbers of peripheral blood monocytes, CD3+, CD4+, CD8+ cells or of any major naïve/memory/activated T-cell subset. The increased IFN-γ production in the AM3 study arm was associated with an increase in the mean of number of IFN-γ molecules produced per CD8+ T cells.

Conclusions: PBMCs of COPD patients showed clear functional T-lymphocyte abnormalities that are rescued by AM3 treatment.

Figures in this Article

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543